Ronner P, Higgins T J, Kimmich G A
Department of Biochemistry and Biophysics, School of Medicine, University of Pennsylvania, Philadelphia 19104.
Diabetes. 1991 Jul;40(7):885-92. doi: 10.2337/diab.40.7.885.
Linogliride is a nonsulfonylurea drug that lowers blood glucose levels in nondiabetic and diabetic humans and animals. Linogliride also stimulates insulin release in vitro. In the perfused pancreas, pretreatment with tolbutamide desensitizes beta-cells to the action of linogliride. We tested the hypothesis that linogliride, like tolbutamide, affects the activity of ATP-sensitive K+ channels, which are thought to control insulin release. We used the whole-cell voltage-clamping technique to measure the K+ current through ATP-sensitive K+ channels in the plasma membrane of single rat beta-cells, which were dialyzed with 30 microM ATP. Linogliride (10-300 microM) inhibited the K+ current; half-maximal inhibition was observed at 6-25 microM, depending on how much time was allowed for equilibration of the drug. Reversal of the inhibition was slow (t1/2 approximately 4 min). In summary, linogliride leads to a decrease in the activity of ATP-sensitive K+ channels.
利诺格列是一种非磺酰脲类药物,可降低非糖尿病和糖尿病患者及动物的血糖水平。利诺格列在体外也能刺激胰岛素释放。在灌注胰腺中,用甲苯磺丁脲预处理会使β细胞对利诺格列的作用不敏感。我们检验了这样一个假设,即利诺格列与甲苯磺丁脲一样,会影响ATP敏感性钾通道的活性,而该通道被认为控制着胰岛素的释放。我们使用全细胞膜片钳技术来测量通过单个大鼠β细胞质膜上ATP敏感性钾通道的钾电流,这些细胞用30微摩尔ATP进行透析。利诺格列(10 - 300微摩尔)抑制钾电流;在6 - 25微摩尔时观察到半数最大抑制,这取决于给予药物平衡的时间。抑制的逆转很慢(半衰期约4分钟)。总之,利诺格列会导致ATP敏感性钾通道的活性降低。